Express News | Kyverna Therapeutics Appoints Mert Aktar to Its Board of Directors
Press Release: Kyverna Therapeutics Appoints Mert Aktar to Its Board of Directors
Kyverna Therapeutics (KYTX): Leading Nano Cap With Promising CAR T-Cell Therapy
UBS Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $13
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc
Kyverna, Cabaletta Started at Buys by UBS on CAR T Therapy Potential
Kyverna Therapeutics Initiated With a Buy at UBS
Rodman & Renshaw Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $16
Kyverna Therapeutics Initiated With a Buy at Rodman & Renshaw
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Maintains Target Price $7
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Kyverna Therapeutics Announces Leadership Update, Warner Biddle Appointed As Chief Executive Officer, Succeeds Peter Maag, Who Has Resigned From His Role As Ceo And A Member Of The Board, Effective Immediately
Express News | Kyverna Therapeutics Inc - Peter Maag Resigns as CEO of Kyverna Therapeutics
Express News | Kyverna Therapeutics Inc - Appoints Warner Biddle as CEO
Press Release: Kyverna Therapeutics Announces Leadership Update
J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday
Kyverna Therapeutics Is Maintained at Neutral by HC Wainwright & Co.
Kyverna Therapeutics Analyst Ratings